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Parasitic infections like amebiasis, trichomoniasis, and giardiasis are major health threats
in tropical and subtropical regions of the world. Metronidazole (MTZ) is the current drug
of choice for amebiasis, giardiasis, and trichomoniasis but it has several adverse effects
and potential resistance is a concern. In order to develop alternative antimicrobials, a
library of 1H-1,2,3-triazole-tethered metronidazole-isatin conjugates was synthesized
using Huisgen’s azide-alkyne cycloaddition reaction and evaluated for their amebicidal,
anti-trichomonal, and anti-giardial potential. Most of the synthesized conjugates exhibited
activities against Trichomonas vaginalis, Tritrichomonas foetus, Entamoeba histolytica,
and Giardia lamblia. While activities against T. vaginalis and T. foetus were comparable
to that of the standard drug MTZ, better activities were observed against E. histolytica
and G. lamblia. Conjugates 9d and 10a were found to be 2–3-folds more potent than
MTZ against E. histolytica and 8–16-folds more potent than MTZ against G. lamblia.
Further analysis of these compounds on fungi and bacteria did not show inhibitory activity,
demonstrating their specific anti-protozoal properties.
Keywords: Entamoeba histolytica, Trichomonas vaginalis, Tritrichomonas foetus, Giardia lamblia, metronidazole,
cytotoxicity, isatin-metronidazole conjugates
INTRODUCTION
Anaerobic protozoan parasites Trichomonas vaginalis and Tritrichomonas foetus are the major
causes of reproductive tract infections viz. trichomoniasis and bovine trichomoniasis (Kumar et al.,
2015; Ravaee et al., 2015). Though men remain asymptomatic, trichomoniasis leads to urogenital
infection in women via sexual transmission, resulting infertility, urethritis, vaginitis, preterm
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delivery and low birth weight, Bovine trichomoniasis, acquired
by direct sexual intercourse, is asymptomatic in nature but
earlier death of developing foetus was observed in some cases.
Multilocus genotyping confirmed that the isolates obtained from
cattle and pig represented the “bovine genotype” of T. foetus and
the cat isolates represented a closely related “feline genotype”
of T. foetus (Fang et al., 2015). The prevalence of T. vaginalis
infection in the United States is estimated to be 2.3 million
among women of 14–49 years and this increases with age
(Sutton et al., 2007; Conrad et al., 2013). Moreover, women
without any past history of sexual intercourse can still be affected
with trichomoniasis (Kumar et al., 2012). Major health threats
associated with trichomoniasis include transmission of HIV-
1 (Fichorova, 2009), benign prostatic hyperplasia (Mitteregger
et al., 2012), prostate cancer and pelvic inflammatory disease
(Stark et al., 2009).
Two other anaerobic intestinal protozoans, Giardia lamblia
and Entamoeba histolytica cause the gastrointestinal diarrheal
diseases (Halliez and Buret, 2013), giardiasis and amebiasis.
Acute gastroenteritis is considered as one of the leading causes
of illnesses and deaths in children under the age of 5 years
(Heresi et al., 2000; Youssef et al., 2000). Infection occurs through
the ingestion of cysts in contaminated water or food and direct
person-to-person contact. Upon ingestion of G. lamblia or E.
histolytica cysts, trophozoitese merge from the cysts and multiply
in the lumen of the small intestine, where G. lamblia attach
to the intestinal mucosa (Navaneethan and Giannella, 2008). E.
histolytica trophozoites invade the colon and causes amoebic
colitis. While 50% of G. lamblia infection is asymptomatic, major
symptoms of amebiasis and giardiasis include weight loss, loss
of appetite, watery or bloody diarrhea, dehydration, bloating
and abdominal cramps, cognitive impairment in children, and
chronic fatigue in adults (Berkman et al., 2002; Hanevik et al.,
2007).
Nitro-imidazoles such as ornidazole (OZ), benznidazole (BZ),
and secnidazole (SZ) (Figure 1) are the widely used medicament
to treat anaerobic infections but have lower efficacies than MTZ
(Nash, 2002). MTZ, an effective synthetic drug introduced in
1960, showed strong inhibitory efficacies against Gram-negative
anaerobic bacteria like Helicobacter pylori and protozoans such
as G. lamblia and E. histolytica. It is the only therapeutic
drug available till date against trichomoniasis (Cudmore et al.,
2004; Sutherland et al., 2010). These outstanding achievements
have encouraged researchers to focus on the development of
nitro-imidazoles with imminent medicinal application. However,
FIGURE 1 | Structures of different derivatives of nitro-imidazoles.
MTZ resistance has been observed in E. histolytica, G. lamblia,
and T. vaginalis and thus the development of novel, non-
cytotoxic and efficient scaffolds against amebiasis, giardiasis,
trichomoniasis, and bacterial infections is desirable (Meri et al.,
2000; Upcroft et al., 2005; Debnath et al., 2013).
Isatin is one of the important pharmacophores with wide
application in drug discovery and it is the core constituent
of many alkaloids, dyes, pesticides, and analytical reagents.
Various studies from the literature show the anti-bacterial
(Sarangapani and Reddy, 1994), anti-fungal (Pandeya et al.,
1999), anti-inflammatory (Bhattacharya and Chakrabarti, 1998)
and anticonvulsant (Popp et al., 1980) properties of isatin-
schiff bases. Thiosemicarbazones are the class of Schiff bases
that exhibit anti-parastic and anti-bacterial properties (Chellan
et al., 2012). Moreover, the spiro compounds of isatin are
also known to exhibit versatile biological properties. Earlier
results based on 1H-1,2,3-triazole and β-amino-alcohol tethered
isatin-β-lactam conjugates showed efficient inhibitory activities
against T. vaginalis (Nisha et al., 2013). Results obtained with
N-propargylated-isatin-Mannich adducts and N-propargylated
isatin-quinoline Mannich adducts against T. foetus have also
prompted the use of isatin as a pharmacophore (Nisha et al.,
2014). Based on the anticancer (Vine et al., 2007; Kumar et al.,
2018; Singh et al., 2018), anticonvulsant (Verma et al., 2004),
antidepressant (Singh et al., 1997), anti-HIV (Bal et al., 2005),
and anti-bacterial (Pandeya et al., 2000) properties of isatin, the
present study explicates the synthesis and biological evaluation
of 1H-1,2,3-triazole-tethered isatin-metronidazole conjugates as
shown in Figure 2. Substitutions at C-5 position of isatin-ring as
well as the introduction of thiosemicarbazide and ketocarbonyl
at C-3 carbonyl of isatin have been carried out to ascertain the
structure-activity relationship of the synthesized conjugates.
EXPERIMENTAL SECTION
General Information
Melting points were determined with open capillaries using a
Veego Precision Digital Melting Point apparatus (MP-D) and
are uncorrected. 1H and 13C NMR were recorded on JEOL
400, Bruker 500 MHz spectrometer, respectively using CDCl3
as solvent. Chemical shifts were reported in parts per million
(ppm) using tetramethylsilane (TMS) as an internal standard
and coupling constants J indicated in Hertz. Splitting patterns
were indicated as s: singlet, d: doublet, t: triplet, m: multiplet,
dd: double doublet, ddd: doublet of a doublet of a doublet,
and br: broad peak. Mass spectrometric analysis was carried out
on BrukermicrOTOF QII equipment using ESI as the source.
Column chromatography was performed on a silica gel (60–120
mesh) using an ethyl acetate: hexane mixture as eluent (Kumar
et al., 2017).
General Procedure for the Synthesis of C-5
Substituted Isatin-Spiro-Ketals (2)
A solution of isatin 1 (1 mmol) in dry DMF was added drop-
wise to a stirred suspension of NaH (1.2 mmol) in dry DMF at
0◦C. The solution was then stirred for 15min. followed by the
drop-wise addition of 2-bromoethanol (1.2 mmol). The reaction
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FIGURE 2 | General Structure of target hybrid compounds.
mixture was allowed to stir at room temperature for 20min. with
subsequent heating at 80◦C for 4 h. The progress was monitored
by TLC. Upon completion, the reaction mixture was extracted
with ethyl acetate (2 × 25mL), washed with brine water (2
× 20mL) and the combined organic layers were dried over
anhydrous Na2SO4. The organic layer was concentrated under
reduced pressure to afford the desired precursors.
General Procedure for the Synthesis of
N-Propargylated C-5 Substituted Isatin
(3)/Isatin Spiroketal (4)
To a stirred suspension of NaH (1 mmol) in dry DMF was added
drop-wise a solution of C-5 substituted isatin (1 mmol) 3 /isatin-
spiroketal 4 in dry DMF at 0◦C. The mixture was stirred for
15min followed by the drop-wise addition of propargyl bromide
(1.2 mmol). The reaction mixture was allowed to stir at room
temperature for 10min. with subsequent heating at 60◦C for 4 h
with progress being monitored by TLC. Upon completion, the
reaction mixture was extracted with ethyl acetate (2 × 25mL)
and washed with brine water (2× 20mL). The combined organic
layers were dried over anhydrous Na2SO4, concentrated under
vacuum to afford the desired precursors.
General Procedure for the Synthesis of
Conjugates, 8a–e and 9a–e
CuSO4.5H2O (0.055 mmol) and sodium ascorbate (0.143 mmol)
were added to a well stirred solution of 5-substituted 1-(prop-2-
yn-1-yl)indoline-2,3-dione 3 (1 mmol) or 5-substituted 1-(prop-
2-yn-1-yl)spiro[indoline-3,2/-[1,3]dioxolan]-2-one 4 and 1-(2-
azidoethyl)-2-methyl-5-nitro-1H-imidazole 7 (1 mmol) in an
ethanol:water (85: 15) mixture. The reactionmixture was allowed
to stir at room temperature for 6–7 h and the progress was
monitored by TLC. Upon completion, the reaction mixture was
extracted with ethyl acetate and water and the combined organic
layers were dried over anhydrous Na2SO4 and concentrated
under vacuum to afford the desired conjugates which were
purified via column chromatography using an ethyl acetate:
hexane (70:30) mixture.
General Procedure for the Synthesis of
Conjugate, 10a–e
Thiosemicarbazide (1 mmol) and glacial acetic acid in
catalytic amount were added to a stirred solution of
5-substituted1-((1-(2-(2-methyl-5-nitro-1H-imidazol-1-
yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)indoline-2,3-dione
(8) in ethanol. The reaction mixture was heated to reflux for
2 h and the progress was monitored using TLC. On completion,
yellow colored solid resulted and this was re-crystallized using
an absolute ethanol to afford the desired conjugates.
MATERIALS AND METHODS
Biological Evaluation
In vitro Susceptibility Assay Against the Bovine
Trichomonad T. foetus Strain D1 and the Feline
Trichomonad T. foetus-Like Strain C1
To perform the initial susceptibility screens on T. foetus D1
(from Lynette Corbeil, University of California at San Diego,
School of Medicine, San Diego, CA, USA) and T. foetus-like C1
(from Stanley Marks, University of California at Davis, School
of Veterinary Medicine, Davis, CA, USA), compounds were
dissolved in 100% DMSO to obtain concentrations of 100mM.
Stock solutions were kept at −20◦C. 5 microliter aliquots of
these solutions were diluted in 5mL of TYM Diamond’s media
(Hardy Diagnostics, Santa Maria, CA, USA) to obtain a final
concentration of 100µM. Metronidazole-sensitive D1 and C1
strains were cultured under anaerobic conditions. After 24 h, cells
were counted using a hemacytometer. The IC50 value for the
series of compounds was determined by inoculating a constant
number of parasite cells in TYM medium and running assays of
increasing drug concentrations, 0.02–100µM, and performing a
regression analysis on percentage growth inhibition relative to
DMSO control, using Prism software, from GraphPad. Predicted
IC50 values of compounds were then confirmed by testing again
using the same assay described above. The sample size consisted
of four independent trials carried out on four different days (to
account for possible variation in the parasite population).
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In vitro Susceptibility Assay Against the Human
Trichomonad T. vaginalis Strain G3
T. vaginalis G3 trophozoites (from Patricia Johnson, University
of California at Los Angeles, CA, USA) were maintained in TYM
media (pH 6.2) at 37◦C for 24 h and every 24 h, 1000 µL of cells
were passed into 10ml of TYM media to maintain the culture.
To perform the initial susceptibility screens on metronidazole-
sensitive T. vaginalis G3, compounds were dissolved in DMSO
to obtain concentrations of 100mM; 5 µL aliquots of these
solutions were diluted in 5mL of TYM medium to obtain a
final concentration of 100µM. After 24 h, cells were counted
using a hemacytometer. The assays were performed in 15mL
culture tubes with T. vaginalis G3 strain. 0.1% DMSO-only
treated parasites served as control to normalize the effects of the
solvent and in vitro conditions. TYM media only control was
also included in the assays. After 24 h, cells were counted using a
hemacytometer. The IC50 values were determined by inoculating
a constant number of parasite cells in TYMmedium and running
assays of increasing compound concentrations, 0.02–100µM,
and performing a regression analysis on percentage growth
inhibition relative to DMSO control, using Prism software
from GraphPad. Predicted IC50 values of compounds were then
confirmed by testing again using the same assay described above.
The sample size consisted of four independent trials carried out
on four different days (to account for possible variation in the
parasite population).
G. lamblia and E. histolytica IC50 Assays
Axenic trophozoites of metronidazole-sensitive G. lamblia
WB and E. histolytica HM1:IMSS were grown in TYI-S-
33 medium supplemented with penicillin (100U/mL) and
streptomycin (100µg/mL). (Diamod et al., 1978; Keister, 1983)
For anti-E. histolytica and anti-G. lamblia IC50assays, 10mM
stocks of the test compounds were serially diluted in DMSO
to achieve a concentration range of 10 mM−78µM. 0.5
microliter of compound from this concentration range was
transferred in triplicate to each well of 96-well plates and
5,000 trophozoites/well were added in a final volume of 100
µL/well. Cultures were grown for 2 days at 37◦C under anaerobic
conditions (GasPak EZ Anaerobe Gas Generating Pouch System
(VWR). Cell growth and viability were determined by adding Cell
Titer-Glo cell viability assay reagent (Promega) and measuring
ATP-dependent luminescence in a microplate reader. Percent
inhibition relative to maximum and minimum reference signal
controls was calculated using the formula:
% Inhibition = [(mean of Maximum Signal Reference
Control—Experimental Value)/(mean of Maximum Signal
Reference Control—mean of Minimum Signal Reference
Control)]× 100.
The 50% inhibitory concentration (IC50) and standard error
(SE) was derived from the concentration-response curves using
Prism software (GraphPad).
Anti-bacterial and Anti-fungal Susceptibility Analyses
To determine if the compound library had other antimicrobial
activities, several fungal and bacterial species were analyzed
for susceptibility to these compounds. Antifungal activity of
compounds was tested in the filamentous fungal pathogen
Aspergillus parasiticus 5862 (National Center for Agricultural
Utilization and Research, USDA-ARS, Peoria, IL, USA) and the
model yeast Saccharomyces cerevisiae BY4741 wild type (Mat a
his311 leu210met1510ura310) (Open Biosystems, Huntsville,
AL, USA). A. parasiticus was cultured at 35◦C on potato dextrose
agar (PDA), and S. cerevisiae was grown on Synthetic Glucose
(SG; Yeast nitrogen base without amino acids 0.67%, glucose
2% with appropriate supplements: uracil 0.02 mg/mL, amino
acids 0.03 mg/mL) or Yeast Peptone Dextrose (YPD; Bacto yeast
extract 1%, Bacto peptone 2%, glucose 2%) medium at 30◦C. All
chemicals for culturing fungi were procured from Sigma Co. (St.
Louis, MO, USA).
To evaluate antifungal activity of compounds inA. parasiticus,
bioassays were performed in microtiter plates (triplicate wells) (3
× 104 to 5 × 104 CFU/mL) with RPMI 1640 medium (Sigma
Co., St. Louis, MO, USA). Compounds were tested at 500µM,
where fungal growth was monitored at 24–48 h after inoculation.
A numerical score from 0 to 4 was provided to each well
according to the protocol outlined by the Clinical and Laboratory
Standards Institute (CLSI) M38-A2 (CLSI, 2008) as follows: 0
= optically clear/no visible growth, 1 = slight growth (25% of
no treatment control), 2 = prominent growth reduction (50%
of no treatment control), 3 = slight growth reduction (75%
of no treatment control), 4 = no growth reduction. To test
antifungal activity of compounds in S. cerevisiae, bioassays were
performed in SG liquid medium (triplicate wells in microtiter
plates). Compounds were examined at 500µM, where antifungal
activity was assessed 24–48 h after inoculation. A numerical score
from 0 to 4 (See above) was provided to each well by the modified
protocols outlined by European Committee on Antimicrobial
Susceptibility Testing (EUCAST) (Keister, 1983).
For anti-bacterial susceptibility testing, disc diffusionmethods
were used. Vehicle control (DMSO) and 100mM stock
compounds were diluted to 100µM inmedia and incubated with
SCHEME 1 | Synthesis of N-propargylated C-5 substituted isatin 3 and
spiroketal N-propargylated C-5 substituted isatin 4.
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empty BDL-sensi-discs (6mm) for 20min at room temperature.
These discs were placed upon plates streaked either with
Lactobacillus reuteri (ATCC 23272), Lactobacillus acidophilus
(ATCC 43560), Lactobacillus rhamnosus (ATCC 53103), Listeria
monocytogenes 10403 (RM2194), Salmonella enterica pGFP, or
Escherichia coli K-12MG 1655. Additionally, various antibiotic
discs [levofloxacin (5 µg), gentamicin (10 µg), and gentamicin
(120µg)] were placed upon these plates as controls for sensitivity.
Plates were streaked for growth of Lactobacilli, grown in
Lactobacilli MRS at 37◦C under anaerobic conditions whereas
the rest of the strains was grown at 37◦C aerobically in Luria
Broth or Brain Heart Infusion Broth. Zones of inhibition
measured in millimeters were measured for each disc.
RESULTS AND DISCUSSION
Synthetic Chemistry
The methodology for the synthesis of isatin-spiroketal 2 involved
sodium hydride promoted reaction of C-5 substituted isatin
1 with 1-bromoethanol (Sigma-Aldrich, Cat No. 48874, CAS
No. 540-51-2) in dry DMF. N-propargylated C-5 substituted
isatin and isatin-spiroketal were obtained via base mediated
reaction of isatin/spiroisatin with propargyl bromide (Sigma-
Aldrich, 80% weight in toluene, Cat No. P51001, CAS No.
106-96-7) in dry DMF at 60◦C (Scheme 1). The precursor
viz. 1-(2-azidoethyl)-2-methyl-5-nitro-1-H-imidazole 7, was
synthesized via initial mesylation of metronidazole 5 (Sigma,
St. Louis, MO, USA, Cat. No. M3761) in dry THF at 0◦C to
form the corresponding methane-sulfonic acid 2-(2-methyl-5-
nitro-imidazol-1-yl)-ethyl ester 6 followed by its nucleophilic
substitution reaction with sodium azide in dry DMF at 60◦C
to afford the corresponding precursor 1-(2-Azido-ethyl)-2-
methyl-5-nitro-1H-imidazole 7 in good yields (Scheme 2).Cu
promoted azide-alkyne cycloaddition reaction of 7 with N-
propargylated-isatin 3 and N-propargylatedspiro-isatin 4 led
to the isolation of desired conjugates 8 and 9 (Scheme 3).
Conjugate 8 was further treated with thiosemicarbazide to
obtain metronidazole-isatin-thiosemicarbazone conjugates 10.
On the bases of spectral data and analytical evidence, structures
were assigned to the synthesized 1H-1,2,3-triazole-tethered
SCHEME 2 | Synthesis of N-alkylazido-metronidazole 7.
SCHEME 3 | Synthesis of isatin-metronidazole conjugates 8, 9, and 10.
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TABLE 1 | In vitro activity of isatin-metronidazole conjugates against T. vaginalis, T. foetus, T. foetus-like pathogen, G. lamblia, and E. histolytica.
Entry % inhibition against
T. vaginalis at
100 µM
IC50 ± S.E (µM) T. vaginalis and T. foetus IC50 ± S.E. (µM)
G. lamblia (WB)
IC50 ± S.E. (µM)
E. histolytica
(HM1:IMSS)
G3 C1 D1
8a 71 N.D N.D 7.0 ± 0.1 11.1 ± 0.1 >50
8b 100 4.7 ± 0.1 2.5 ± 0.02 1.5 ± 0.1 6.7 ± 0.01 >50
8c 100 7.1 ± 0.2 7.2 ± 0.1 N.D 3 ± 0.01 15.8 ± 0.03
8d 14 N.D N.D 12.8 ± 0.3 14.5 ± 0.05 >50
8e 100 N.D N.D N.D 1.6 ± 0.01 2.3 ± 0.03
9a 100 82.3 ± 0.2 4.8 ± 0.02 18.3 ± 0.3 4 ± 0.07 7.9 ± 0.02
9b 100 7.8 ± 0.04 19 ± 0.3 16.5 ± 0.2 2.1 ± 0.01 19.5 ± 0.03
9c 100 3.2 ± 0.09 1.1 ± 0.02 N.D 1.3 ± 0.01 1.6 ± 0.03
9d 100 1.4 ± 0.02 12.9 ± 0.06 18.7 ± 0.04 0.8 ± 0.01 1.5 ± 0.03
9e 100 2.4 ± 0.02 7.8 ± 0.04 0.3 ± 0.03 1.2 ± 0.01 1.2 ± 0.08
10a 100 2.6 ± 0.08 0.6 ± 0.02 0.9 ± 0.03 0.4 ± 0.01 2.5 ± 0.02
10b 100 1.4 ± 0.02 5.3 ± 0.02 4.7 ± 0.02 0.5 ± 0.05 2.3 ± 0.02
10c 100 5.2 ± 0.03 50.8 ± 0.2 11.1 ± 0.03 7.2 ± 0.07 28.7 ± 0.04
10d 100 1.2 ± 0.04 2.0 ± 0.04 44.0 ± 0.08 5.9 ± 0.02 ND
10e 41 N.D N.D N.D 16.2 ± 0.08 >50
MTZ 0.72 6.4 5
N.D., not determined.
isatin-metronidazole conjugates (see Supplementary Material).
The compound 8c, for example was characterized as
5-chloro-1-{1-[2-(2-methyl-5-nitro-imidazol-1-yl)-ethyl]-
1H-[1,2,3]triazol-4-ylmethyl}-1H-indole-2,3-dione analyzed for
C17H14ClN7O4 and showed molecular ion peak at m/z 416.4302
([M+H]+) and 417.4318 ([M+2]+) in its mass spectrum. The
salient feature of its (Ravaee et al., 2015) H NMR spectra include
charterstick peak at δ 4.60 (t, J = 4.8Hz, 2H); δ 4.75 (t, J =
5.8Hz, 2H) and one singlet at 4.90 (2H) ppm corresponding
to methylene group, respectively. Two singlets also appeared
at δ 7.93 and 7.97 which correspond to triazole and imidazole
proton (Navaneethan and Giannella, 2008). C NMR spectrum of
compound 8c exhibited the appearance of characteristic peaks at
δ 182.40 and 157.90 which correspond to isatin carbonyl (C=O)
and amidic carbonyl of isatin (=N-C=O). Three methylenic
carbons show characteristic peaks at δ 35.3, 46.5 and 49.3 along
with one single peak at 13.3 corresponding to—CH3 group of
imidazole ring.
In vitro Evaluation Against T. vaginalis,
T. foetus, T. foetus-Like, G. lamblia, E.
histolytica, Fungal, and Bacterial Species
The chemical library of metronidazole-isatin conjugates was
evaluated in a general inhibitory screen against protozoal
pathogen T. vaginalis and the percentage inhibition results at
different concentrations are enlisted in Table 1. As evident most
of the conjugates exhibited 100% growth inhibition at 100µM
except 8a, 8d, and 10e (Table 1). The potent conjugates were
further evaluated for their IC50 against different strains of
T. vaginalis and T. foetus and compared with metronidazole,
(Table 1). A closer inspection of Table 1 revealed an interesting
structure activity relationship with activity being dependent upon
the nature of substituent at C-3 and C-5 positions of isatin ring.
In case of MTZ susceptible G-3 strain, introduction of a ketal
and thiosemicarbazone substituent at C-3 position improved
the activity profiles as evident from conjugates 9a–e and 10a–d.
Further, the presence of halogen substituent (F, Cl, Br) improved
the activity profiles with the most potent conjugate 10d (R=Br)
exhibiting an IC50 value of 1.2µM against G-3 strain, which is
comparable to MTZ.
Similar SAR has been observed against C1 strain of T. foetus-
like pathogen with activity mainly dependent upon the nature
of substituent at C-3 position. The replacement of ketocarbonyl
with ketal in general improved the activity profiles with conjugate
9c (R=Cl) exhibiting an IC50 value of 1.1 µM. However,
the introduction of thiosemicarbazide functionality substantially
improved the efficacy of the conjugates with compound 10a
(R=H) displaying an IC50 value of 0.6µM, better than the
standard drug MTZ. The synthesized conjugates were also
evaluated against D1 strain of T. foetus. The conjugate 10a again
proved to be the most potent among the series, exhibiting an
IC50 value of 0.9µM. The generalized SAR of the synthesized
conjugates against T. vaginalis and T. foetus has been provided
in Figure 3.
Encouraged with these biological results, it was considered
worthwhile to examine the activities of synthesized conjugates
against other anaerobic protozoans such as WB strain of G.
lamblia and HM1 strain of E. histolytica. Since trophozoites
are the relevant forms that cause trichomoniasis, amebiasis
and giardiasis, we tested the activity of compounds against
trophozoite forms. As evident from IC50 values enlisted in
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FIGURE 3 | Generalized SAR of the synthesized compounds against T. vaginalis and T. foetus.
FIGURE 4 | Generalized SAR of the synthesized compounds against G. lamblia and E. histolytica.
Table 1, all conjugates exhibited good activity profiles with
IC50 values ranging from 0.4 to 16.2µM against WB strain of
G. lamblia. Activity profiles showed a preference for electron
withdrawing substituent (R= F, Cl, Br, NO2) at C-5 position
of isatin except 10a (R=H) which exhibited an IC50 value
of 0.4µM. The replacement of ketocarbonyl with ketal and
thiosemicarbazide improved the activities except 8e which
displayed an IC50 value of 1.6µM. Conjugates 8c, 8e, 9a, 9b,
9c, 9d, 9e, 10a, 10b, and 10d proved to be more potent than
the standard drug MTZ (IC50 = 6.4µM) (Arendrup et al., 2012),
with conjugates 9d, 10a, and 10b exhibiting IC50 values in sub-
micromolar concentration. Similarly, conjugates 8e, 9c, 9d, 9e,
10a, and 10b showed better potency than the current standard
of care MTZ (IC50 = 5µM)(Bashyal et al., 2017) against E.
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histolytica (Table 1). The generalized SAR of the synthesized
conjugates against E. histolytica andG. lamblia has been provided
in Figure 4.
To determine if these compounds were specific for protozoal
parasites, we also tested a number of different fungal and bacterial
species. In all assays, the activities of these compounds were
specific for protozoa and exerted no detectable antifungal and
antibacterial properties.
In conclusion, the present study undertook the synthesis of
1H-1,2,3-triazole-tethered metronidazole-isatin conjugates and
evaluated their activity against multiple protozoan parasites,
namely T. vaginalis, T. foetus, T. foetus-like pathogen, G. lamblia
and E. histolytica. SAR studies revealed the dependence of
activity profiles on the nature of substituent at C-3 and C-5
positions of isatin ring with most of the synthesized conjugates
exhibiting comparable efficacies to that of MTZ against
different trichomonal strains while better inhibitory activities
were observed against G. lamblia. Interestingly, introduction
of thiosemicarbazide into the basic core of the synthesized
conjugates improved the activities with most potent conjugate
10a being∼16 foldsmore active thanMTZ againstG. lamblia,∼2
folds more active than MTZ against E. histolytica and equipotent
to MTZ against T. vaginalis and T. foetus. Further work on
improving the activities of most promising conjugates of the
synthesized library, is presently underway.
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